Results 91 to 100 of about 1,577 (196)

Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome observed in high-risk neuroblastoma

Frontiers in Pharmacology, 2012
Disease recurrence is frequent in high-risk neuroblastoma (NBL) patients even after multimodality aggressive treatment [a combination of chemotherapy, surgical resection, local radiation therapy, autologous stem cell transplantation (ASCT) and cis ...
Tony A. Koehn, Lori L. Scardino, Kory L. Alderson, Amy K. Erbe, Kim A. McDowell, Bartosz eGrzywacz, Jacquelyn A. Hank, Paul Mark Sondel   +7 more
doaj   +1 more source

89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding

, 2018
Cergutuzumab amunaleukin (CEA-IL2v) is an immunocytokine directed against carcinoembryonic antigen (CEA) containing an IL2v-moiety with abolished IL-2 receptor (IL-2R) α binding.
Schellens, Jan H M, Saro, Jose, Marcel P.M. Stokkel, Marc C. Huisman, Tapan K. Nayak, Mulder, Emma R, Van Dongen, Guus A M S, C. Willemien Menke-van der Houven van Oordt, Afd Pharmacoepi & Clinical Pharmacology, Emma R. Mulder, Pharmacoepidemiology and Clinical Pharmacology, Danielle J. Vugts, Jan H.M. Schellens, Hoekstra, Otto S, Vugts, Danielle J, Guus A.M.S. Van Dongen, Linda J. de Wit-van der Veen, Nayak, Tapan K, Verheul, Henk M, Menke-van der Houven van Oordt, C Willemien, Jean J. L. Tessier, Jose Saro, Emilie M.J. van Brummelen, Stefan Evers, Stokkel, Marcel P M, Tessier, Jean J L, Henk M. Verheul, de Wit-van der Veen, Linda J, Evers, Stefan, Otto S. Hoekstra, van Brummelen, Emilie M J, Huisman, Marc C, Sub Clinical Pharmacology   +32 more
core   +1 more source

Immunocytokines

Cancer is a leading cause of death worldwide. Although many treatments are available, immunotherapy has recently expanded the therapeutic options by stimulating the patient’s own immune system to kill tumor cells. One form of immunotherapy is antibody therapy. Antibodies can directly inhibit tumor growth or indirectly recruit immune cells to kill tumor
openaire   +2 more sources

Computational Design and Evaluation of ScFv-IFN-β Fusion Protein against HER1-positive Breast Cancer

JLUMHS
OBJECTIVE: To computationally design immunocytokines capable of targeting cancer cell antigens and modulating the immune response, representing a promising therapeutic approach for HER1-positive breast cancer METHODOLOGY: This study was conducted at ...
Muhammad Islam Khan, Muhammad Hassan, Muhammad Hamza Afandi, Aamir Sohail, Nadeem Ahmad, Muhammad Idrees, Rashid Bhatti, Mohsin Ahmad Khan   +7 more
doaj   +1 more source

A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control

Nature Communications, 2019
Interleukin-2 (IL-2) based cancer therapy is limited by severe toxicity and strong Treg amplification at the therapeutic dosage. Here, the authors develop a recombinant IL-2 immunocytokine which is comprised of a tumor-targeting antibody fused to a super
Zhichen Sun, Zhenhua Ren, Kaiting Yang, Zhida Liu, Shuaishuai Cao, Sisi Deng, Lily Xu, Yong Liang, Jingya Guo, Yingjie Bian, Hairong Xu, Jiyun Shi, Fan Wang, Yang-Xin Fu, Hua Peng   +14 more
doaj   +1 more source

Generation and purification of mIFN-γ and hIFN-γ immunocytokines targeting CD70.

, 2013
(A) Two plasmids – pMAZ-IgH and pMAZ-IgL – were used as backbones to construct and express anti-CD70 immunocytokines bearing either murine (m) or human (h) IFN-γ.
Peirong Chen (403320), Shoko Nogusa (347948), Heidi Simmons (403323), Gregory P. Adams (269450), Siddharth Balachandran (66976), Calvin Shaller (403322), Suraj Peri (70543), Roshan J. Thapa (403321)   +7 more
core   +1 more source

immunocytokine

Citation: 'immunocytokine' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.13280 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms.
openaire   +1 more source

The immunocytokine NHS-IL12 as a potential cancer therapeutic

Oncotarget, 2014
Targeted delivery of IL-12 might turn this cytokine into a safer, more effective cancer therapeutic. Here we describe a novel immunocytokine, NHS-IL12, consisting of two molecules of IL-12 fused to a tumor necrosis-targeting human IgG1 (NHS76). The addition of the human IgG1 moiety resulted in a longer plasma half-life of NHS-IL12 than recombinant IL ...
Jonathan, Fallon, Robert, Tighe, Giorgio, Kradjian, Wilson, Guzman, Anna, Bernhardt, Berend, Neuteboom, Yan, Lan, Helen, Sabzevari, Jeffrey, Schlom, John W, Greiner   +9 more
openaire   +3 more sources

Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects [PDF]

, 2015
Purpose: Radiotherapy modifies the tumor microenvironment and causes the release of tumor antigens, which can enhance the effect of immunotherapy. L19 targets the extra domain B (ED-B) of fibronectin, a marker for tumor neoangiogenesis, and can be used ...
Ludwig J. Dubois, Dario Neri, Erik A.L. Biessen, Dana H.F. Quaden, Ala Yaromina, Lieuwes, Natasja G., Boon, L., Neri, Dario, Quaden, Dana H. F., Wieten, Lotte, Wilfred T.V. Germeraad, Lambin, Philippe, Troost, Esther G. C., Nicolle H. Rekers, Rekers, Nicolle H., Louis Boon, Dubois, Ludwig J., Natasja G. Lieuwes, Catharina M.L. Zegers, Philippe Lambin, Biessen, Erik A. L.; id_orcid, Lotte Wieten, Yaromina, Ala, Germeraad, Wilfred T. V., Zegers, Catharina M. L., Esther G.C. Troost, Troost EG, Boon L, Lambin P, Wieten L, Dubois LJ, Yaromina A, Germeraad WT, Lieuwes NG, Quaden DH, Neri D, Biessen EA, Zegers CM, Rekers NH   +38 more
core   +1 more source

High-Affinity Fully Human Anti-EpCAM Antibody with Biased IL-2 Exhibits Potent Antitumor Activity

Biomolecules
Monoclonal antibodies (mAbs) are widely used in cancer therapy but often show limited efficacy for solid tumors. Enhancing anti-tumor activity by fusing cytokines to tumor-targeting mAbs, which specifically activate immune cells within the tumor ...
Zhi Wang, Mingkai Wang, Quanxiao Li, Yanling Wu, Tianlei Ying   +4 more
doaj   +1 more source